Similarly, MYSTIC demonstrated that in NSCLC w/PDL1 ≥ 25%, durvalumab + tremelimumab was not better than chemotherapy and may be inferior to durvalumab alone [49]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.